{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:08:31Z","timestamp":1790701711187,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jpet.2026.105001","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:23:02Z","timestamp":1785799382000},"page":"105001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing ribavirin for oncology: Integrating metabolism, signaling, and translational control"],"prefix":"10.1016","volume":"393","author":[{"given":"Amrita","family":"Talukder Mohini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3570-8888","authenticated-orcid":false,"given":"Chibuike Emmanuel","family":"Okafor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6359-6257","authenticated-orcid":false,"given":"Joseph M.","family":"Schober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0859-3803","authenticated-orcid":false,"given":"Bhargav A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jpet.2026.105001_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11302-016-9509-4","article-title":"Guanosine and its role in neuropathologies","volume":"12","author":"Bettio","year":"2016","journal-title":"Purinergic Signal"},{"issue":"3","key":"10.1016\/j.jpet.2026.105001_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.bbagrm.2018.09.011","article-title":"mRNA cap regulation in mammalian cell function and fate","volume":"1862","author":"Galloway","year":"2019","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"11","key":"10.1016\/j.jpet.2026.105001_bib3","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/CIRCRESAHA.106.144501","article-title":"cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology","volume":"100","author":"Zaccolo","year":"2007","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-23-0437","article-title":"GTP signaling links metabolism, DNA repair, and responses to genotoxic stress","volume":"14","author":"Zhou","year":"2024","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.jpet.2026.105001_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/med.20104","article-title":"Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery","volume":"28","author":"Shu","year":"2008","journal-title":"Med Res Rev"},{"issue":"11","key":"10.1016\/j.jpet.2026.105001_bib6","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/cdd.2015.47","article-title":"Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity","volume":"22","author":"Bianchi-Smiraglia","year":"2015","journal-title":"Cell Death Differ"},{"issue":"11","key":"10.1016\/j.jpet.2026.105001_bib7","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/jm00281a014","article-title":"Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides","volume":"15","author":"Witkowski","year":"1972","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int"},{"issue":"Suppl 5","key":"10.1016\/j.jpet.2026.105001_bib9","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1093\/cid\/ciu623","article-title":"Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies","volume":"59","author":"Chemaly","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jpet.2026.105001_bib10","series-title":"Progress in Drug Research","first-page":"41","article-title":"Pleiotropic mechanisms of ribavirin antiviral activities","author":"Hong","year":"2002"},{"issue":"2","key":"10.1016\/j.jpet.2026.105001_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2009-02-205153","article-title":"Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin","volume":"114","author":"Assouline","year":"2009","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jpet.2026.105001_bib12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.3606.3606","article-title":"A phase I combination study of ribavirin and low dose cytarabine arabinoside (ara-C) in M4\/M5 acute myeloid leukemia (AML) and AML with high eIF4E","volume":"118","author":"Assouline","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jpet.2026.105001_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hed.24938","article-title":"Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA\/IVB human papillomavirus-associated oropharyngeal squamous cell cancer","volume":"40","author":"Dunn","year":"2018","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2006.10.062","article-title":"Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters","volume":"557","author":"Yamamoto","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.jpet.2026.105001_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.31083\/ph.2020.0440","article-title":"Transport of ribavirin in human myelogenous leukemia cell line K562","volume":"75","author":"Takano","year":"2020","journal-title":"Pharmazie"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0020-711X(90)90140-X","article-title":"The metabolism of ribavirin in erythrocytes and nucleated cells","volume":"22","author":"Page","year":"1990","journal-title":"Int J Biochem"},{"issue":"3","key":"10.1016\/j.jpet.2026.105001_bib17","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/mol.63.3.538","article-title":"Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets","volume":"63","author":"Gallois-Montbrun","year":"2003","journal-title":"Mol Pharmacol"},{"issue":"11","key":"10.1016\/j.jpet.2026.105001_bib18","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1016\/j.bmcl.2007.03.018","article-title":"Structural effects on the phosphorylation of 3-substituted 1-beta-D-ribofuranosyl-1,2,4-triazoles by human adenosine kinase","volume":"17","author":"Kumarapperuma","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"10.1016\/j.jpet.2026.105001_bib19","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1535-7163.MCT-18-0666","article-title":"The use of ribavirin as an anticancer therapeutic: will it go viral?","volume":"18","author":"Casaos","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.jpet.2026.105001_bib20","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3109\/10428194.2010.496506","article-title":"Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?","volume":"51","author":"Borden","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jpet.2026.105001_bib21","first-page":"1971","article-title":"Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation","volume":"29","author":"K\u00f6k\u00e9ny","year":"2009","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.jpet.2026.105001_bib22","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3892\/or.2015.3816","article-title":"Ribavirin as a tri-targeted antitumor repositioned drug","volume":"33","author":"De la Cruz-Hernandez","year":"2015","journal-title":"Oncol Rep"},{"issue":"6","key":"10.1016\/j.jpet.2026.105001_bib23","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1021\/bi00406a057","article-title":"Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase","volume":"27","author":"Yamada","year":"1988","journal-title":"Biochemistry"},{"issue":"2\u20133","key":"10.1016\/j.jpet.2026.105001_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0162-3109(00)00193-4","article-title":"The structure of inosine 5\u2032-monophosphate dehydrogenase and the design of novel inhibitors","volume":"47","author":"Sintchak","year":"2000","journal-title":"Immunopharmacology"},{"issue":"52","key":"10.1016\/j.jpet.2026.105001_bib25","doi-asserted-by":"crossref","first-page":"50654","DOI":"10.1074\/jbc.M208330200","article-title":"Crystal structure of Tritrichomonas foetus inosine monophosphate dehydrogenase in complex with the inhibitor ribavirin monophosphate reveals a catalysis-dependent ion-binding site","volume":"277","author":"Prosise","year":"2002","journal-title":"J Biol Chem"},{"issue":"24","key":"10.1016\/j.jpet.2026.105001_bib26","doi-asserted-by":"crossref","first-page":"9049","DOI":"10.1158\/0008-5472.CAN-04-1553","article-title":"Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5\u2032-monophosphate dehydrogenase","volume":"64","author":"Floryk","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib27","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/s41598-024-85094-5","article-title":"Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer","volume":"15","author":"da Silva Fernandes","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yexcr.2016.11.001","article-title":"Autophagy suppression sensitizes glioma cells to IMP dehydrogenase inhibition-induced apoptotic death","volume":"350","author":"Isakovic","year":"2017","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jpet.2026.105001_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/1878-0261.70226","article-title":"IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion","author":"Yag\u00fce-Capilla","year":"2026","journal-title":"Mol Oncol"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib30","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41401-024-01411-8","article-title":"IMPDH inhibitors upregulate PD-L1 in cancer cells without impairing immune checkpoint inhibitor efficacy","volume":"46","author":"Zheng","year":"2025","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1021\/jm00379a018","article-title":"Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase","volume":"28","author":"Gebeyehu","year":"1985","journal-title":"J Med Chem"},{"issue":"11 Pt 1","key":"10.1016\/j.jpet.2026.105001_bib32","first-page":"5512","article-title":"Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture","volume":"45","author":"Lee","year":"1985","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jpet.2026.105001_bib33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.163","article-title":"Ribavirin targets eIF4E dependent Akt survival signaling","volume":"375","author":"Tan","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"2 Pt A","key":"10.1016\/j.jpet.2026.105001_bib34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canlet.2014.01.018","article-title":"The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator","volume":"356","author":"Faubert","year":"2015","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.jpet.2026.105001_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2025.101306","article-title":"Oblique-incidence reflectivity difference technology identifies the antiviral drug Ribavirin as an inhibitor of lung tumor progression by targeting AMPK signaling","volume":"16","author":"Gao","year":"2026","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.jpet.2026.105001_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.155038","article-title":"Ribavirin attenuates carcinogenesis by downregulating IL-6 and IL-8 in vitro in human lung adenocarcinoma","volume":"253","author":"De Rubis","year":"2024","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jpet.2026.105001_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110305","article-title":"Metabolomics study of ribavirin in the treatment of orthotopic lung cancer based on UPLC-Q-TOF\/MS","volume":"370","author":"Zhu","year":"2023","journal-title":"Chem Biol Interact"},{"issue":"18","key":"10.1016\/j.jpet.2026.105001_bib38","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1038\/sj.onc.1207545","article-title":"eIF-4E expression and its role in malignancies and metastases","volume":"23","author":"De Benedetti","year":"2004","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.jpet.2026.105001_bib39","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1042\/BST20150126","article-title":"Signalling to eIF4E in cancer","volume":"43","author":"Siddiqui","year":"2015","journal-title":"Biochem Soc Trans"},{"issue":"52","key":"10.1016\/j.jpet.2026.105001_bib40","doi-asserted-by":"crossref","first-page":"18105","DOI":"10.1073\/pnas.0406927102","article-title":"Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap","volume":"101","author":"Kentsis","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.jpet.2026.105001_bib41","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.bbrc.2013.03.125","article-title":"Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate","volume":"434","author":"Volpon","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.jpet.2026.105001_bib42","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1261\/rna.2132505","article-title":"The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro","volume":"11","author":"Westman","year":"2005","journal-title":"RNA"},{"issue":"8","key":"10.1016\/j.jpet.2026.105001_bib43","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1261\/rna.2930805","article-title":"Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap","volume":"11","author":"Yan","year":"2005","journal-title":"RNA"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ab.2012.11.020","article-title":"Solution-based approach to study binding to the eIF4E cap-binding site using CD spectroscopy","volume":"434","author":"Garvie","year":"2013","journal-title":"Anal Biochem"},{"issue":"12","key":"10.1016\/j.jpet.2026.105001_bib45","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1261\/rna.2238705","article-title":"Further evidence that ribavirin interacts with eIF4E","volume":"11","author":"Kentsis","year":"2005","journal-title":"RNA"},{"issue":"19","key":"10.1016\/j.jpet.2026.105001_bib46","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1073\/pnas.1524291113","article-title":"Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E","volume":"113","author":"Volpon","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.jpet.2026.105001_bib47","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-10-2334","article-title":"Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer","volume":"17","author":"Pettersson","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2016.02.052","article-title":"eIF4E-phosphorylation-mediated Sox2 upregulation promotes pancreatic tumor cell repopulation after irradiation","volume":"375","author":"Yu","year":"2016","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib49","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.bbrc.2016.12.025","article-title":"Inhibition of mTOR\/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma","volume":"482","author":"Dai","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.jpet.2026.105001_bib50","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.amjms.2017.03.025","article-title":"Antiviral drug ribavirin targets thyroid cancer cells by inhibiting the eIF4E-\u03b2-catenin axis","volume":"354","author":"Shen","year":"2017","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jpet.2026.105001_bib51","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.biopha.2017.10.034","article-title":"Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy","volume":"96","author":"Wang","year":"2017","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.jpet.2026.105001_bib52","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.bbrc.2018.10.124","article-title":"Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity","volume":"506","author":"Chen","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.jpet.2026.105001_bib53","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s12094-017-1786-z","article-title":"Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma","volume":"20","author":"Cao","year":"2018","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22007","article-title":"Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation","volume":"32","author":"Tan","year":"2018","journal-title":"J Biochem Mol Toxicol"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib55","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.bbrc.2018.06.150","article-title":"Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer","volume":"503","author":"Xi","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib56","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbrc.2019.01.117","article-title":"Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer","volume":"510","author":"Jin","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"13","key":"10.1016\/j.jpet.2026.105001_bib57","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41388-018-0567-7","article-title":"Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia","volume":"38","author":"Urtishak","year":"2019","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib58","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbrc.2019.04.053","article-title":"Ribavirin sensitizes nasopharyngeal carcinoma to 5-fluorouracil through suppressing 5-fluorouracil-induced ERK-dependent-eIF4E activation","volume":"513","author":"Hu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib59","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.bbrc.2019.03.118","article-title":"Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma","volume":"512","author":"Xu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.jpet.2026.105001_bib60","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.bbrc.2020.05.127","article-title":"Inhibition of eIF4E signaling by ribavirin selectively targets lung cancer and angiogenesis","volume":"529","author":"Tan","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jpet.2026.105001_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109689","article-title":"Phosphorylation of the mRNA cap-binding protein eIF4E and cancer","volume":"73","author":"Yang","year":"2020","journal-title":"Cell Signal"},{"key":"10.1016\/j.jpet.2026.105001_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115450","article-title":"Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation","volume":"415","author":"Ge","year":"2021","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib63","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bcpt.13736","article-title":"Ribavirin inhibits cell proliferation and metastasis and prolongs survival in soft tissue sarcomas by downregulating both protein arginine methyltransferases 1 and 5","volume":"131","author":"Zhang","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jpet.2026.105001_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115829","article-title":"Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5","volume":"435","author":"Tian","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"issue":"21","key":"10.1016\/j.jpet.2026.105001_bib65","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1038\/onc.2016.457","article-title":"Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic","volume":"36","author":"Volpin","year":"2017","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.jpet.2026.105001_bib66","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.18632\/oncotarget.23883","article-title":"Ribavirin as a potential therapeutic for atypical teratoid\/rhabdoid tumors","volume":"9","author":"Casaos","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.jpet.2026.105001_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14500","article-title":"Investigating the effect of polymerase inhibitors on cellular proliferation: computational studies, cytotoxicity, CDK1 inhibitory potential, and LC-MS\/MS cancer cell entrapment assays","volume":"103","author":"Farouk","year":"2024","journal-title":"Chem Biol Drug Des"},{"issue":"8","key":"10.1016\/j.jpet.2026.105001_bib68","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/cas.12183","article-title":"Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming","volume":"104","author":"Kosaka","year":"2013","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib69","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1038\/s41467-021-23974-4","article-title":"Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer","volume":"12","author":"Takayama","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1868-7083-3-8","article-title":"Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines","volume":"3","author":"Sappok","year":"2011","journal-title":"Clin Epigenetics"},{"issue":"6","key":"10.1016\/j.jpet.2026.105001_bib71","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1016\/j.ygeno.2020.08.034","article-title":"Development and validation of a six-RNA binding proteins prognostic signature and candidate drugs for prostate cancer","volume":"112","author":"Gao","year":"2020","journal-title":"Genomics"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib72","article-title":"Multi-omics analysis of macrophage-associated receptor and ligand reveals a strong prognostic signature and subtypes in hepatocellular carcinoma","volume":"14","author":"Zhao","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpet.2026.105001_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1373011","article-title":"Identification of oxidative stress-related biomarkers in uterine leiomyoma: a transcriptome-combined Mendelian randomization analysis","volume":"15","author":"Li","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"10.1016\/j.jpet.2026.105001_bib74","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2174\/0109298673307257240826111754","article-title":"Discovery of small molecule inhibitors targeting CTNNB1 (\u03b2-catenin) for endometrial cancer: employing 3D QSAR, drug-likeness assessment, ADMET predictions, molecular docking and simulation","volume":"33","author":"Fatima","year":"2024","journal-title":"Curr Med Chem"},{"issue":"16","key":"10.1016\/j.jpet.2026.105001_bib75","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.1080\/07391102.2024.2321237","article-title":"Computational insights into KRAS G12C inhibition: exploring possible repurposing of Azacitidine and Ribavirin","volume":"43","author":"Sharma","year":"2025","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.jpet.2026.105001_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122859","article-title":"Computational and biological approaches in repurposing ribavirin for lung cancer treatment: unveiling antitumorigenic strategies","volume":"352","author":"Paudel","year":"2024","journal-title":"Life Sci"},{"issue":"7","key":"10.1016\/j.jpet.2026.105001_bib77","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1080\/15257770.2024.2369093","article-title":"Identification of lung adenocarcinoma subtypes based on mitochondrial energy metabolism-related genes","volume":"44","author":"Ding","year":"2025","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"Suppl 17","key":"10.1016\/j.jpet.2026.105001_bib78","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2105-16-S17-S5","article-title":"A computational method for drug repositioning using publicly available gene expression data","volume":"16","author":"Shabana","year":"2015","journal-title":"BMC Bioinformatics"},{"issue":"2","key":"10.1016\/j.jpet.2026.105001_bib79","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.burns.2023.09.009","article-title":"The biomarkers associated with epithelial-mesenchymal transition in human keloids","volume":"50","author":"Qiu","year":"2024","journal-title":"Burns"},{"issue":"8","key":"10.1016\/j.jpet.2026.105001_bib80","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib81","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/1078-0432.CCR-14-2362","article-title":"Molecular pathways: the eIF4F translation initiation complex-new opportunities for cancer treatment","volume":"23","author":"Malka-Mahieu","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jpet.2026.105001_bib82","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.18632\/oncotarget.802","article-title":"Advances in targeting signal transduction pathways","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2026.105001_bib83","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0014-2999(00)00596-3","article-title":"Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G(1)","volume":"404","author":"Vall\u00e9e","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2026.105001_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136746","article-title":"Ribavirin inhibits the activity of mTOR\/eIF4E, ERK\/Mnk1\/eIF4E signaling pathway and synergizes with tyrosine kinase inhibitor imatinib to impair Bcr-Abl mediated proliferation and apoptosis in Ph+ leukemia","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"issue":"33","key":"10.1016\/j.jpet.2026.105001_bib85","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1074\/jbc.C116.740498","article-title":"AMP-activated protein kinase up-regulates mitogen-activated protein (MAP) kinase-interacting serine\/threonine kinase 1a-dependent phosphorylation of eukaryotic translation initiation factor 4E","volume":"291","author":"Zhu","year":"2016","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib86","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12964-026-02901-4","article-title":"Translational control of AMPK activity in melanoma","volume":"24","author":"Vadovi\u010dov\u00e1","year":"2026","journal-title":"Cell Commun Signal"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib87","doi-asserted-by":"crossref","first-page":"501","DOI":"10.33549\/physiolres.934618","article-title":"The role of AMPK\/mTOR signaling pathway in anticancer activity of metformin","volume":"70","author":"Chomanicova","year":"2021","journal-title":"Physiol Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib88","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41420-024-02011-5","article-title":"AMPK-a key factor in crosstalk between tumor cell energy metabolism and immune microenvironment?","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov"},{"issue":"19","key":"10.1016\/j.jpet.2026.105001_bib89","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1073\/pnas.1505787112","article-title":"CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation","volume":"112","author":"Shuda","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.jpet.2026.105001_bib90","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.molcel.2017.12.024","article-title":"Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function","volume":"69","author":"Wan","year":"2018","journal-title":"Mol Cell"},{"issue":"12","key":"10.1016\/j.jpet.2026.105001_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225860","article-title":"Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells","volume":"14","author":"Wambecke","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.jpet.2026.105001_bib92","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1158\/1535-7163.MCT-19-0572","article-title":"Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma","volume":"19","author":"Huq","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.jpet.2026.105001_bib93","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1007\/s00210-023-02841-7","article-title":"Comparison of anti-cancer effects of platinum ribavirin and ribavirin via telomerase and Bcl-2 gene expression","volume":"397","author":"Sabokrouh","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"10.1016\/j.jpet.2026.105001_bib94","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/0008-5472.CAN-14-1996","article-title":"Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis","volume":"75","author":"Pettersson","year":"2015","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jpet.2026.105001_bib95","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/labinvest.2016.77","article-title":"Migration and epithelial-to-mesenchymal transition of lung cancer can be targeted via translation initiation factors eIF4E and eIF4GI","volume":"96","author":"Attar-Schneider","year":"2016","journal-title":"Lab Invest"},{"issue":"9","key":"10.1016\/j.jpet.2026.105001_bib96","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1158\/0008-5472.CAN-12-0329","article-title":"Translation initiation factor eIF4E is a target for tumor cell radiosensitization","volume":"72","author":"Hayman","year":"2012","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib97","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3171\/2020.8.PEDS20561","article-title":"Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma","volume":"27","author":"Huq","year":"2021","journal-title":"J Neurosurg Pediatr"},{"issue":"7507","key":"10.1016\/j.jpet.2026.105001_bib98","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature13283","article-title":"The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation","volume":"511","author":"Zahreddine","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jpet.2026.105001_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168378","article-title":"Medicinal chemistry and NMR driven discovery of novel UDP-glucuronosyltransferase 1A inhibitors that overcome therapeutic resistance in cells","volume":"436","author":"Osborne","year":"2024","journal-title":"J Mol Biol"},{"issue":"11","key":"10.1016\/j.jpet.2026.105001_bib100","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.3324\/haematol.2023.282791","article-title":"Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory\/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine","volume":"108","author":"Assouline","year":"2023","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.jpet.2026.105001_bib101","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1134\/S0026893325601119","article-title":"The impact of ARL13B regulation on IMPDH-based cytoophidia formation and PC-3 cells\u2019 proliferation and migration","volume":"59","author":"Sadeghi","year":"2025","journal-title":"Mol Biol"},{"issue":"12","key":"10.1016\/j.jpet.2026.105001_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029690","article-title":"Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells","volume":"6","author":"Carcamo","year":"2011","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.jpet.2026.105001_bib103","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.carres.2009.05.017","article-title":"Synthesis of novel ribavirin hydrazone derivatives and anti-proliferative activity against A549 lung cancer cells","volume":"344","author":"Liu","year":"2009","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.jpet.2026.105001_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112009","article-title":"Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin","volume":"188","author":"Sabat","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/15257770.2022.2107218","article-title":"Synthesis of ribavirin 1,2,3- and 1,2,4-triazolyl analogs with changes at the amide and cytotoxicity in breast cancer cell lines","volume":"42","author":"Way","year":"2023","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib106","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1021\/jm800927r","article-title":"Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity","volume":"52","author":"Wan","year":"2009","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib107","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1081\/NCN-120022032","article-title":"Synthesis of triazole nucleoside derivatives","volume":"22","author":"Li","year":"2003","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"43","key":"10.1016\/j.jpet.2026.105001_bib108","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.2174\/0113816128275084231202153602","article-title":"Synthetic 1,2,4-triazole-3-carboxamides induce cell cycle arrest and apoptosis in leukemia cells","volume":"29","author":"Ekaterina","year":"2023","journal-title":"Curr Pharm Des"},{"issue":"20","key":"10.1016\/j.jpet.2026.105001_bib109","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.3390\/molecules29204808","article-title":"Synthesis of alkyl\/aryloxymethyl derivatives of 1,2,4-triazole-3-carboxamides and their biological activities","volume":"29","author":"Mikhina","year":"2024","journal-title":"Molecules"},{"issue":"1\u20132","key":"10.1016\/j.jpet.2026.105001_bib110","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1081\/NCN-120027838","article-title":"Synthesis of azole nucleoside 5\u2032-monophosphate mimics (P1Ms) and their inhibitory properties of IMP dehydrogenases","volume":"23","author":"Wang","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"6","key":"10.1016\/j.jpet.2026.105001_bib111","doi-asserted-by":"crossref","first-page":"952","DOI":"10.5012\/jkcs.2011.55.6.952","article-title":"Synthesis and cytotoxicity evaluation of phosphorylated derivatives of ribavirin","volume":"55","author":"Rao","year":"2011","journal-title":"J Korean Chem Soc"},{"key":"10.1016\/j.jpet.2026.105001_bib112","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jddst.2018.05.027","article-title":"Synthesis of nucleoside-boronic esters hydrophobic pro-drugs: a possible route to improve hydrophilic nucleoside drug loading into polymer nanoparticles","volume":"46","author":"Abo-zeid","year":"2018","journal-title":"J Drug Deliv Sci Technol"},{"issue":"5","key":"10.1016\/j.jpet.2026.105001_bib113","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3390\/pharmaceutics17050631","article-title":"Impact of pH-responsive cisplatin\/ribavirin-loaded monodispersed magnetic silica nanocomposite on A549 lung cancer cells","volume":"17","author":"Almohazey","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib114","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s12010-019-03090-2","article-title":"Viramidine-loaded galactosylated nanoparticles induce hepatic cancer cell apoptosis and inhibit angiogenesis","volume":"190","author":"Abd-Rabou","year":"2020","journal-title":"Appl Biochem Biotechnol"},{"issue":"1","key":"10.1016\/j.jpet.2026.105001_bib115","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1186\/s12885-022-10201-6","article-title":"Implication of extrinsic and intrinsic apoptotic pathways in the targeted therapy of hepatocellular carcinoma using aptamer-labeled viramidine nanoparticles","volume":"22","author":"Abd-Rabou","year":"2022","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jpet.2026.105001_bib116","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11095-017-2283-3","article-title":"Taribavirin and 5-fluorouracil-loaded pegylated-lipid nanoparticle synthesis, p38 docking, and antiproliferative effects on MCF-7 breast cancer","volume":"35","author":"Abd-Rabou","year":"2018","journal-title":"Pharm Res"},{"key":"10.1016\/j.jpet.2026.105001_bib117","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.saa.2012.07.020","article-title":"DNA interaction studies of a platinum (II) complex containing an antiviral drug, ribavirin: the effect of metal on DNA binding","volume":"96","author":"Shahabadi","year":"2012","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"issue":"5","key":"10.1016\/j.jpet.2026.105001_bib118","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2174\/0115672018305548240614113451","article-title":"Ribavirin in modern antitumor therapy: prospects for intranasal administration","volume":"22","author":"Mikhel","year":"2025","journal-title":"Curr Drug Deliv"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526012012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526012012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:45:40Z","timestamp":1790700340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526012012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":118,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0022356526012012"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105001","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing ribavirin for oncology: Integrating metabolism, signaling, and translational control","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105001"}}